IASLC World Conference on Lung Cancer | Conference

Dr. Sheffield on the Economic Cost of Delaying of Treatment in NSCLC

August 9th 2022

Brandon S. Sheffield, MD, discusses the economic cost of delaying treatment while conducting biomarker testing in non–small cell lung cancer.

Dr. Levy on the Efficacy of Datopotamab Deruxtecan Plus Pembrolizumab in NSCLC

August 9th 2022

Benjamin Levy, MD, discusses the efficacy findings of the combination of datopotamab deruxtecan and pembrolizumab, with or without chemotherapy, in non–small cell lung cancer.

Boosting Lung Cancer Screening Will Improve Survival

August 9th 2022

There is an obvious way to double survival in patients with lung cancer in the next 5 years: remove barriers to screening, especially for high-risk populations.

Datopotamab Deruxtecan/Pembrolizumab With or Without Chemotherapy Elicits Responses in Advanced NSCLC

August 9th 2022

The combination of datopotamab deruxtecan and pembrolizumab, with or without platinum-based chemotherapy, displayed promising efficacy and a manageable safety profile in patients with advanced/metastatic non–small cell lung cancer.

Pembrolizumab/Etoposide Maintains Meaningful Survival Benefit in Untreated ES-SCLC

August 9th 2022

The combination of pembrolizumab and etoposide maintained benefits in overall survival (OS) and progression-free survival vs etoposide plus placebo in patients with previously untreated extensive-stage small cell lung cancer.

Frontline Tremelimumab Plus Durvalumab Generates Survival Benefits in Select mNSCLC Subgroups

August 9th 2022

First-line treatment with tremelimumab, durvalumab, and chemotherapy elicited overall survival and progression-free survival benefits in patients with metastatic nonsquamous cell non–small cell lung cancer harboring STK11, KEAP1, and KRAS mutations.

Dr. Spira on the Further Investigations of Lazertinib/Amivantamab in EGFR-Mutant NSCLC

August 8th 2022

Alexander I. Spira, MD, PhD, FACP, discusses additional studies investigating the use of lazertinib and amivantamab in EGFR-mutated non–small cell lung cancer.

Talazoparib Plus Low-Dose Temozolomide Improves ORR Over Historical Control in R/R ES-SCLC

August 8th 2022

The combination of talazoparib and temozolomide elicited an objective response rate of 39.3% in patients with extensive-stage small cell lung cancer who were relapsed or refractory to a frontline platinum-based chemotherapy regimen, according to data from a phase 2 UCLA/TRIO-US L-07 trial.

Dr. Marmarelis on the Efficacy of Lazertinib/Amivantamab Plus Chemotherapy in EGFR-Mutated NSCLC

August 8th 2022

Melina Elpi Marmarelis, MD, discusses the efficacy of lazertinib and amivantamab-vmjw plus chemotherapy in patients with EGFR-mutated non–small cell lung cancer.

Temozolomide Plus Nivolumab Shows Efficacy in Previously Treated ES-SCLC

August 8th 2022

Temozolomide in combination with nivolumab induced a promising overall response rates in patients who previously received chemotherapy for extensive-stage small cell lung cancer.

Limited Role for Second-line Chemotherapy Remains for Patients With NSCLC With Progression on Chemoimmunotherapy

August 8th 2022

New combinations and strategies are needed for patients with non–small cell lung cancer who progress after first-line chemoimmunotherapy after results of a retrospective analysis showed modest efficacy with second-line chemotherapy.

Real-World Analysis Pushes EGFR C797X as Leading Resistance Mechanism to First- and Second-line Osimertinib in NSCLC

August 8th 2022

EGFR C797X mutations have become a leading mechanism of acquired resistance following treatment with the third-generation EGFR inhibitor osimertinib, outpacing MET amplification.

Amivantamab/Lazertinib/Chemo Combo Achieves 50% ORR in Pretreated EGFR-Mutant NSCLC

August 8th 2022

Amivantamab in combination with lazertinib plus carboplatin and pemetrexed elicited encouraging responses in pretreated patients with EGFR-mutant non–small cell lung cancer, according to findings from the phase 1 CHRYSALIS-2 trial.

IMpower010 Data Show OS Trend in Favor of Adjuvant Atezolizumab Vs BSC in PD-L1+ Resected NSCLC

August 8th 2022

An overall survival trend in favor of adjuvant atezolizumab over best supportive care was observed in patients with stage II to IIIA resected non–small cell lung cancer with a PD-L1 tumor cell (TC) expression of at least 1%, with a clinically meaningful OS trend noted in those with a PD-L1 TC expression of 50% or higher.

Neoadjuvant Nivolumab Plus Chemo Improves Survival Vs Chemo Alone in Resectable Stage IIIA/B NSCLC

August 8th 2022

The addition of nivolumab to chemotherapy provided progression-free survival and overall survival benefits compared with chemotherapy alone in patients with stage IIIA/B non–small cell lung cancer.

Pembrolizumab Plus Lenvatinib Elicits Positive Clinical Activity in Recurrent Pleural Mesothelioma

August 7th 2022

The combination of pembrolizumab and lenvatinib generated promising clinical activity with a manageable safety profile in pretreated patients with malignant pleural mesothelioma.

Sotorasib Plus SHP2 Inhibition Elicits Promising Preliminary Activity in KRAS G12C–Mutated NSCLC

August 7th 2022

The combination of sotorasib and the small molecule SHP2 inhibitor RMC-4630 led to an investigator-assessed objective response rate of 27% and 50% in pretreated and KRAS G12C inhibitor–naïve patients with non–small cell lung cancer, respectively.

VISION Trial Cohort C Data Confirm Robust Efficacy of Tepotinib in METex14-Altered NSCLC

August 7th 2022

The robust efficacy achieved with tepotinib in patients with non–small cell lung cancer harboring MET exon 14 skipping alterations was independently confirmed in data from the primary analysis of cohort C of the phase 2 VISION trial.

Dr. Hong on the Significance of Larotrectinib in NTRK-Positive NSCLC

August 7th 2022

David S. Hong, MD, discusses the significance of larotrectinib in the treatment of non–small cell lung cancer and other solid tumors harboring NTRK gene fusions.

Dr. Iams on the Evaluation of Sotorasib in KRAS G12C–Mutant Solid Tumors

August 7th 2022

Wade T. Iams, MD, discusses the evaluation of sotorasib in KRAS G12C–mutant solid tumors, including non–small cell lung cancer.